Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease including surgical closure of left atrial appendage

aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease. The operation as well as the pre and post-operative care will be performed according to local surgical policies.

Surgical closure of left atrial appendage

Aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.

aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.

No closure of left atrial appendage

Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery and removal of balloon using the BALT GOLDBAL2 balloon and BALTACCIBDPE100 catheter.

Fetoscopic Endoluminal Tracheal Occlusion (FETO) surgery will be completed at 27 weeks 0 days - 29 weeks 6 days gestation.

Fetoscopic removal of the balloon occlusion will be performed at 34 weeks 0 days to 34 weeks 6 days gestation.

Fetoscopic Endoluminal Tracheal Occlusion Surgery

Janice Scudmore, NP

Fetuses with Left CDH (O/E LHR \< 25%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)

This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH (O/E \< 25%; O/E LHR \< 30 %) and right CDH (O/E LHR \< 45%).

Fetoscopic Endoluminal Tracheal Occlusion (FETO)

Fetuses with Left CDH (O/E LHR \< 30%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)

Fetuses with Right CDH (O/E LHR \< 45%) will receive Fetoscopic Endoluminal Tracheal Occlusion (FETO)

임상시험 현황

좌심방 부속기의 수술적 폐쇄, 좌심방 부속기 폐쇄 없음

태아경을 이용한 기관내 폐쇄 수술

태아경 기관내강 폐쇄술(FETO)

GORE® CARDIOFORM ASD 폐쇄기